For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Extension Study of Ataluren Treatment for Nonsense Mutation Dystrophinopathy
This study is an extension of the Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy. The purpose of this study is to better understand whether Ataluren can be safely given for a long period of time.
The study will also provide additional information as to whether the actions of Ataluren can result in improved walking, activity, muscle function, muscle fragility, upper limb function, pulmonary function and health-related quality of life in boys with Duchenne muscular dystrophy.